Cargando…

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma

Detalles Bibliográficos
Autores principales:	Krönke, Jan, Knop, Stefan, Langer, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739718/ https://www.ncbi.nlm.nih.gov/pubmed/29290933 http://dx.doi.org/10.18632/oncotarget.22572

Ejemplares similares

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
por: Merz, Maximilian, et al.
Publicado: (2020)

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
por: Díaz, Tania, et al.
Publicado: (2017)

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
por: Bjorklund, C C, et al.
Publicado: (2015)

Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide
por: Ito, Tomoki, et al.
Publicado: (2018)

Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide
por: Vaxman, Iuliana, et al.
Publicado: (2020)

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
por: Ng, Yuen Lam Dora, et al.
Publicado: (2022)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone
por: Sato, Shuku, et al.
Publicado: (2018)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone
por: Yasui, Taku, et al.
Publicado: (2020)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
por: Pourabdollah, Maryam, et al.
Publicado: (2016)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma
por: Isozumi, Yu, et al.
Publicado: (2013)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma
por: Sagar, FNU, et al.
Publicado: (2018)

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
por: Moreau, Philippe, et al.
Publicado: (2019)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma
por: Marchetti, Monia, et al.
Publicado: (2021)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Lenalidomide-Induced Diffuse Alveolar Hemorrhage in Patient With Multiple Myeloma
por: Qanash, Sultan, et al.
Publicado: (2023)

Lenalidomide induces degradation of IKZF1 and IKZF3
por: Krönke, Jan, et al.
Publicado: (2014)

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2011)

Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
por: Khan, Abdullah M., et al.
Publicado: (2018)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
por: Cippitelli, Marco, et al.
Publicado: (2021)

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
por: Dimopoulos, Meletios, et al.
Publicado: (2020)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
por: Schwamborn, Katharina, et al.
Publicado: (2011)

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
por: Martiniani, Roberta, et al.
Publicado: (2012)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1cukb5pgp01hgrpt153n083kfs